Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #709

    https://en.m.wikipedia.org/wiki/Ocrelizumab Ved læsning af denne ses dog en del problemer grundet det pressede immunforsvar ved Ocrelizumab behandling.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #710

      Problemet for ocrelizumab er bare at det tager ½ år ved behandlingsstop før ødelæggelsen af B-cellerne ophører og immunforsvaret dermed genvinder sin styrke. Ofa kan stoppes på en md hvis nødvendigt.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #711

        Det er vel ikke et problem for ofa. Men det der kan være problemet er jo om det betyder noget. Naturligvis er effekt jo en meget vigtig parameter. Men hvis pts nu kan leve med RRMS i meget lang tid vil bivirkningerne være vigtige. Vi må se data 🙂

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #712

          https://www.ocrelizumabinfo.global/content/dam/ocrelizumab/global/en/documents/P4_2_025_AAN_2019_SafetyUpdatePoster_Global_Hauser_et_al_Supplemental_Mats_V2.pdf Analyse af sideeffects ved ocrelizumab.

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #713

            Så har vi benchmark her.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #714

              Tak Solsen. 🙂

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #715

                God morgen. 🙂

                1 Reply Last reply
                0
                • T Offline
                  T Offline
                  transalp
                  wrote on sidst redigeret af
                  #716

                  Go morgen.. 🙂

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bibob
                    wrote on sidst redigeret af
                    #717

                    God morgen fra syden. 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #718

                      Ser ikke ud til det store rebound idag.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #719

                        not sure if this new trial was posted already : Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma https://clinicaltrials.gov/ct2/show/NCT04052997?term=Camidanlumab&rank=1

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #720

                          ADC Therapeutics IPO:

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #721

                            Just a moment...

                            favicon

                            (www.firstwordpharma.com)

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #722

                              yes, that made me revisit this. here is the SEC form F1 https://sec.report/Document/0001140361-19-016305/

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #723

                                it contains a short explanation of ADCT-301 and also : Key elements of our strategy are outlined below:

                                • .
                                • Advance our second lead product candidate, ADCT-301, to support BLA submission in the first half of 2022.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #724

                                  and then i also thought "Risks Related to Our Relationship with Third Parties" was interesting as it says "Our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize ADCT-301."

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #725

                                    Our collaboration and license agreement with Genmab requires a divestment of ADCT-301, in which Genmab has a 25% interest, following database lock for the Phase 1/2 clinical trial. The agreement sets out a defined process to facilitate the divestment of ADCT-301 by licensing the rights thereto to a third party, subject to Genmab’s right of first opportunity to negotiate to acquire ADCT-301 in full.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #726

                                      p148 is also interesting

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #727

                                        the Lundbeck Parkinson's trial a bit delayed, doesn't seem to recruit very enthusiastically https://clinicaltrials.gov/ct2/history/NCT03611569?A=2&B=3&C=merged#StudyPageTop

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #728

                                          Kursen søger ned mod styrkeområdet 1360-80. Tror der ligger den del s.l i det område.Vi må håbe de 1360 holder.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger